Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exelixis’ Cabozantinib Cleared For Kidney Cancer, With Competitive Labeling

This article was originally published in The Pink Sheet Daily

Executive Summary

Company plans to launch within two weeks, priced at a premium to competing drugs in kidney cancer.

You may also be interested in...



Exelixis Has Renewed Momentum Heading Into 2021

The approval of Cabometyx in combination with Opdivo as a first-line treatment for RCC will power substantial growth at Exelixis into 2022.

Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown

Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.

Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting

During its July 2016 meeting, the EU's top scientific advisory panel, the Committee for Medicinal Products for Human Use, recommended approval for two anticancers, cabozantinib and lenvatinib, that will likely shake up the advanced kidney cancer sector, and a new therapy for pancreatic cancer, liposomal and pegylated irinotecan.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS079349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel